Class IIB: Device-Specific ISO Standards
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Acuerdo No. 0631-ARSA-2023, the Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario, provides in Article 45 that the dossier for Class IIB devices consists of the items listed in Articles 43 and 44 plus one addition: the currently valid version of the ISO standard corresponding to the device. The provision lists by way of example ISO 13485, ISO 10993-1, ISO 14155 NTC, ISO 14155 and ISO 6872, and keeps the open-ended wording of or another ISO standard in line with the specific type of medical device (u otra norma ISO acorde al tipo específico de dispositivo médico). The GRZAN regulatory team notes: Article 45 is the only provision in the regulation that writes its documentation requirement in an examples-plus-open-ended manner — the Class IIB document list is therefore not fixed, and the ISO set must be argued item by item against the device type. A poorly argued selection will trigger a request for additional documents, and that supplement consumes the six-month window of the risk classification report.
2. Legal basis
The table below maps the requirements relevant to Class IIB to their provisions and key points.
| Level | Instrument | Provision | Key point |
|---|---|---|---|
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 45, item 1 | Class IIB must first satisfy all materials of Articles 43 and 44 |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 45, item 2 | Currently valid ISO standard corresponding to the device; the provision lists 13485, 10993-1, 14155 NTC, 14155 and 6872 |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 45, item 2 | Open-ended wording: u otra norma ISO acorde al tipo específico de dispositivo médico |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 46, item 3 | Class III adds certified testing for biocompatibility, stability, cytotoxicity and electrical safety |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 43, item 13 | ISO conformity document when the label bears the word sterile or a similar symbol (applies to all classes) |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 29 | Class IIB is high risk; special controls must be applied at the design and production stages to demonstrate safety and effectiveness |
| Regulation | Acuerdo No. 0631-ARSA-2023, Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario | Article 90 | The regulation is revised in line with international regulatory progress, so ISO version requirements change accordingly |
3. Expert insights
Insight 1: the examples-plus-open-ended drafting of Article 45 cuts both ways. The benefit is that companies can select the ISO standard that best fits the device; the risk is that the selection must be argued. The GRZAN regulatory team recommends adding a page to the dossier titled ISO applicability statement, explaining item by item which device characteristics the selected standards address (material contact, implantation, clinical studies, dental materials, and so on), turning the open-ended requirement into a reviewable argument.
Insight 2: ISO 10993-1 corresponds to biological evaluation, ISO 14155 to clinical studies. By placing the two families side by side, the provision is effectively organising standards by evaluation dimension rather than by product category: 10993-1 addresses the biological reaction between materials and the human body, while 14155 addresses the conduct of clinical trials. Which one to choose depends on the evidence you use to demonstrate safety, not on the medical specialty the product belongs to.
Insight 3: ISO 6872 is the dental ceramics standard, showing the list reaches specialty materials. The inclusion of 6872 indicates that ARSA’s expected scope covers specialty devices such as dental restorative materials. For dental and orthopaedic material products, the note is that the device-specific ISO is often a better fit than the generic ISO, so specialty standards should be searched first.
Insight 4: the testing requirements of Class IIB and Class III differ; do not perform Class III tests prematurely. Article 45 requires only the corresponding ISO standards (the standard texts or conformity evidence), whereas Article 46, item 3, requires certified testing (biocompatibility, stability, cytotoxicity, electrical safety). The difference in cost and lead time is substantial — classify first, then decide whether testing is needed.
Insight 5: the ISO version requirement is current and valid. Article 44, item 2, and Article 45, item 2, both say en su versión vigente. Combined with Article 90’s statement that the regulation is revised with international progress, companies should verify before submission that the ISO certificate they hold reflects the current version; outdated certificates may be challenged for renewal during review.
4. Practical recommendations
- Add an ISO applicability statement page to the Class IIB dossier, arguing item by item how each selected standard corresponds to the device characteristics.
- Select standards by evaluation dimension: 10993-1 for material contact, 14155 for clinical studies, and dedicated standards searched for specialty materials.
- Classify first, then decide on testing: Class IIB submits standards, Class III submits certified testing.
- Before submission, verify that the ISO certificate version is the currently valid one.
- Discuss the selected ISO standards with ARSA at the classification stage to avoid supplements consuming the six-month window of the classification report.
- Record the selected ISO standards in the internal product file as the baseline for renewal and change comparisons.
5. Verification checklist
- □ An ISO applicability statement has been written for the Class IIB product
- □ The selected standards have been argued by evaluation dimension (biological, clinical, specialty materials)
- □ The testing scope has been fixed by class (IIB submits standards; III submits testing)
- □ The ISO certificate version has been confirmed as currently valid
- □ The selected ISO list has been discussed with ARSA at the classification stage
- □ The selected ISO list has been recorded in the internal product file
Related reading: [Article 22 — What Class IIA adds](/honduras-medical-device-registration/class-iia-iso-13485-and-software/) | [Article 24 — What Class III adds](/honduras-medical-device-registration/class-iii-additional-requirements/) | [Article 09 — The four risk classes I, IIA, IIB and III](/honduras-medical-device-registration/four-risk-classes-i-iia-iib-iii/)
Regulatory information verified as of October 29, 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Honduran market. Our team manages Secretariat of Health (SESAL) registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us